Vascularites

Vascularites

  
Guillevin L et al. French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80.Lire le résumé
Miloslavsky EM et al. Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2014 Nov;66(11):3151-9Lire le résumé
Sacri AS et al. Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. Nephrol Dial Transplant. 2015 Feb 12.Lire le résumé
Jachiet M et al. French Vasculitis Study Group. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol. 2015 Feb;67(2):527-34.Lire le résumé
Pagnoux C et al. French Vasculitis Study Group. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015 Apr;67(4):1117-27.Lire le résumé
Miloslavsky EM et al. for the Rituximab in ANCA-Associated Vasculitis–Immune Tolerance Network Research Group. Outcomes of Nonsevere Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated With Glucocorticoids
Arthritis Rheumatol. 2015 June;67(6):1629-36.
Lire le résumé
McGeoch L et al. ; Vasculitis Clinical Research Consortium. Cardiac Involvement in Granulomatosis with Polyangiitis. J Rheumatol. 2015 Jul;42(7):1209-12.Lire le résumé
Puéchal X et al. Long-term outcomes of the WEGENT trial on remission-maintenance for granulomatosis with polyangiitis or microscopic polyangiitis. Arthritis Rheumatol Hoboken NJ. 16 oct 2015.Lire le résumé
Rahmattulla C et al. Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013. Arthritis Rheumatol. 2015 Dec;67(12):3270-8.Lire le résumé
Mohammad AJ et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. févr 2016; 75(2):396‑401.Lire le résumé
Crickx E et al. Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two Patients. Arthritis Rheumatol Hoboken NJ. mars 2016;68(3):702‑12.Lire le résumé
Cartin-Ceba R et al. Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. Arthritis Rheumatol Hoboken NJ. juin 2016;68(6):1467‑76.Lire le résumé
Unizony S et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. juin 2016;75(6):1166‑9.Lire le résumé
Jachiet M et al. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis Rheumatol Hoboken NJ. sept 2016;68(9):2274‑82.Lire le résumé
Miloslavsky EM et al. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener’s): Distinct Patient Subsets. Arthritis Rheumatol Hoboken NJ. déc 2016;68(12):2945‑52.Lire le résumé
Morishita KA et al. Early Outcomes in Children with Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV). Arthritis Rheumatol Hoboken NJ. 2017 Mar 28Lire le résumé
Tan JA et al. Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann Rheum Dis. 2017 May 3Lire le résumé
Wechsler ME et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017 18;376(20):1921–32.Lire le résumé
Bossuyt X et al. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017 Nov;13(11):683–92. Lire le résumé
(1) Schreiber A et al. C5a receptor mediates neutrophil activation and ANCAinduced
glomerulonephritis. J Am Soc Nephrol. 2009 Feb;20(2):289-98.
(2) Xiao H et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN.
J Am Soc Nephrol. 2014 Feb;25(2):225-31.
(3) Jayne DRW et al. CLEAR Study Group. Randomized Trial of
C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017
Sep;28(9):2756-2767.
Lire le résumé
Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB, et al. Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases. 2018 Jun 27;annrheumdis-2017-212861Lire le résumé
Banerjee S, Bagheri M, Sandfort V, Ahlman MA, Malayeri AA, Bluemke DA, et al. Vascular calcification in patients with large-vessel vasculitis compared to patients with hyperlipidemia. Seminars in Arthritis and Rheumatism [Internet]. 2018 Sep [cited 2018 Nov 26]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0049017218304098 Lire le résumé
Jones RB, Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Annals of the Rheumatic Diseases. 2019 Jan 5;annrheumdis-2018-214245Lire le résumé
Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study. Mayo Clinic Proceedings. 2018 May;93(5):597–606

Mourguet M, Chauveau D, Faguer S, Ruidavets JB, Béjot Y, Ribes D, et al. Increased schemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis. Journal of Autoimmunity. 2019 Jan;96:134–41

Kang A, Antonelou M, Wong NL, Tanna A, Arulkumaran N, Tam FWK, et al. High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody–associated Vasculitis. The Journal of Rheumatology. 2019 Mar;46(3):285–93
Lire le résumé
Jones RB, Furuta S, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. juin 2015;74(6):1178‐82

Stones JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med. 15 juill 2010;363(3):221‐32

Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. The Lancet. mai 2014;383(9930):1731‐8

Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki Disease. J Pediatr. déc 2008;153(6):833‐838.e6
Lire le résumé
Gregersen JW, Erikstrup C, Ivarsen P, Glerup R, Krarup E, Keller KK, et al. PR3-ANCA-associated vasculitis is associated with a specific motif in the peptide-binding cleft of HLA-DP molecules. Rheumatology [Internet]. 1 avr 2019 [cité 26 avr 2019]; Disponible sur:
https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/kez111/5425275
Lire le résumé